Edition:
United States

Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

8.76USD
23 Sep 2016
Change (% chg)

$-0.07 (-0.79%)
Prev Close
$8.83
Open
$8.84
Day's High
$9.00
Day's Low
$8.73
Volume
85,465
Avg. Vol
122,567
52-wk High
$13.15
52-wk Low
$6.01

CYTK.OQ

Chart for CYTK.OQ

About

Cytokinetics, Incorporated is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its lead drug... (more)

Overall

Beta: 1.50
Market Cap(Mil.): $347.81
Shares Outstanding(Mil.): 39.70
Dividend: --
Yield (%): --

Financials

  CYTK.OQ Industry Sector
P/E (TTM): -- 42.52 36.60
EPS (TTM): -1.07 -- --
ROI: -51.56 -0.26 13.91
ROE: -68.19 -3.05 14.82

BRIEF-Cytokinetics announces additional results from COSMIC-HF

* Announces additional results from COSMIC-HF to be presented at the HFSA Annual Scientific Meeting Source text for Eikon: Further company coverage:

Sep 09 2016

BRIEF-Cytokinetics reports initiation of IND-enabling studies

* Enabling studies for a next-generation fast skeletal muscle activator under co's collaboration with astellas

Sep 08 2016

BRIEF-Cytokinetics and Amgen to advance Omecamtiv Mecarbil to phase 3

* Cytokinetics and Amgen to advance Omecamtiv Mecarbil to phase 3 clinical development

Sep 01 2016

BRIEF-Cytokinetics expects results from VITALITY-ALS in 2H 2017

* Cytokinetics completes enrollment in VITALITY-ALS, phase 3 clinical trial of Tirasemtiv in patients with ALS

Aug 17 2016

BRIEF-Cytokinetics Inc reports q2 2016 financial results

* Will not update financial guidance until Q3 earnings due to recent expansion of collaboration with Astellas

Jul 28 2016

BRIEF-Cytokinetics, Astellas announce option right for Tirasemtiv

* Cytokinetics and Astellas announce option right for Tirasemtiv and expansion of global collaboration for CK-2127107 in ALS

Jul 27 2016

BRIEF-Cytokinetics Q1 loss per share $0.31

* Cytokinetics, inc. Reports first quarter 2016 financial results

Apr 28 2016

BRIEF-Cytokinetics announces start of Phase 2 clinical trial of Omecamtiv Mecarbil

* Cytokinetics announces start of phase 2 clinical trial of Omecamtiv Mecarbil in Japanese subjects with heart failure Source text for Eikon: Further company coverage:

Apr 04 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$127.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.